Gilead Sciences Inc share price logo

Gilead Sciences Inc Share Price

NASDAQ: GILD

Large Cap

$140.43

+1.40

(+1.01%)

as on

Gilead Sciences Inc Stock Performance

as on April 15, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $137.93
    $141.40
    downward going graph

    1.78%

    Downside

    0.69%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $93.37
    $157.29
    downward going graph

    33.51%

    Downside

    12.01%

    Upside

    downward going graph

Gilead Sciences Inc share price movements today

Previous Close
$139.03
Open
$138.12
Volume
3.7M
Day's Low - High
$137.93 - $141.40
52 Week Low - High
$93.37 - $157.29

Gilead Sciences Inc Historical Returns

1 Month Return
-4.11 %
3 Month Return
+ 12.06 %
1 Year Return
+ 30.54 %
3 Year Return
+ 67.51 %
5 Year Return
+ 112.91 %

Gilead Sciences Inc Stock Fundamentals & Key Indicators

Check Gilead Sciences Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$172.5B

EPS (TTM)

8.6582

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.23%

PE Ratio (TTM)

20.5

Industry PE ratio

20.783

PEG Ratio

0.387

EBITDA

14.6B

Revenue (TTM)

29.4B

Profit Margin

28.90%

Return On Equity TTM

40.66%

Gilead Sciences Inc Stock Valuation

Track how Gilead Sciences Inc P/E has moved over time to understand its valuation trends.

Gilead Sciences Inc in the last 5 years

  • Overview

  • Trends

Lowest (7.99x)

September 30, 2021

Today (20.50x)

April 14, 2026

Industry (20.78x)

April 14, 2026

Highest (22.09x)

March 31, 2026

LowHigh

Today’s Price to Earnings Ratio: 20.50x

Gilead Sciences Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Gilead Sciences Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Gilead Sciences Inc image
Gilead Sciences Inc
HOLD$172.5B112.91%20.528.90%
AstraZeneca PLC image
AstraZeneca PLC
BUY$316.3B305.78%31.1517.41%
Eli Lilly and Company image
Eli Lilly and Company
BUY$840.8B407.95%40.9931.67%
Johnson & Johnson image
Johnson & Johnson
BUY$574.7B48.8%21.628.46%
AbbVie Inc image
AbbVie Inc
BUY$367.8B94.97%87.746.91%
See all

Stock Returns calculator for Gilead Sciences Inc Stock including INR - Dollar returns

The Gilead Sciences Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Gilead Sciences Inc investment value today

Current value as on today

₹1,42,637

Returns

₹42,637

(+42.64%)

Returns from Gilead Sciences Inc Stock

₹31,859 (+31.86%)

Dollar Impact

₹10,778 (+10.78%)

Analyst Recommendation on Gilead Sciences Inc Stock

Based on 38 analysts

HOLD

47.37%

Buy

52.63%

Hold

0.00%

Sell

Based on 38 analysts, 52.63% of analysts recommend a 'HOLD' rating for Gilead Sciences Inc. Average target price of $157.86

Gilead Sciences Inc Share Price Target

Get share price movements and forecasts by analysts on Gilead Sciences Inc.

What analysts predicted

11.04%UPSIDE

Target Price

$157.86

Current Price

$140.43

Analyzed by

38 Analysts

Target

$157.86

Gilead Sciences Inc target price $157.86, a slight upside of 11.04% compared to current price of $140.43. According to 38 analysts rating.

Gilead Sciences Inc Stock’s Investor Sentiment and Interest

Investment in Gilead Sciences Inc Shares on INDmoney has grown by 17.64% over the past 30 days, indicating increased transactional activity.

Time period: to

Change:17.64% versus previous 30 day period

Search interest for Gilead Sciences Inc Stock has decreased by -37% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-37% versus previous 30 day period

Gilead Sciences Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
7,050
7,114
6,686
6,953
7,545
7,569
6,667
7,081
7,769
7,925
Gross Profit
5,485
5,024
5,134
5,409
5,971
5,988
5,127
5,580
6,200
6,882
Operating Income
2,623
1,612
-4,322
2,644
888
2,452
2,237
2,474
3,327
2,964
EBITDA
3,234
2,593
-3,542
2,984
1,884
3,109
2,605
3,374
4,583
2,333
Interest Expense
232
252
254
237
238
249
260
254
256
255
Depreciation
684
688
690
694
690
693
696
691
686
687
Income Before Tax
2,318
1,653
-4,486
2,053
956
2,167
1,649
2,429
3,641
2,078
Income Tax Expense
146
237
-315
438
-297
385
334
468
589
-105
Net Income
2,180
1,429
-4,170
1,614
1,253
1,783
1,315
1,960
3,052
2,183
Net Profit Margin
30.92%
20.09%
-62.37%
23.21%
16.61%
23.56%
19.72%
27.68%
39.28%
27.55%

Gilead Sciences Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
30,390
26,107
22,127
22,449
24,689
27,305
27,281
27,116
28,754
29,443
Gross Profit
26,129
21,736
17,274
17,774
20,117
20,704
21,624
27,116
22,503
25,523
Operating Income
17,633
14,124
8,200
4,287
4,071
9,918
7,330
7,605
1,662
11,817
EBITDA
19,219
15,933
10,305
7,559
4,133
11,329
8,852
7,605
4,434
10,820
Interest Expense
964
1,118
1,077
995
984
1,001
935
944
977
1,024
Depreciation
-
1,286
1,429
1,404
1,480
2,050
2,103
2,533
2,767
2,760
Income Before Tax
17,097
13,529
7,799
5,160
1,669
8,278
5,814
6,859
690
9,796
Income Tax Expense
3,609
8,885
2,339
-204
1,580
2,077
1,248
-1,247
211
1,286
Net Income
13,501
4,628
5,455
5,386
123
6,225
4,592
5,665
480
8,510
Net Profit Margin
44.43%
17.73%
24.65%
23.99%
0.50%
22.80%
16.83%
20.89%
1.67%
28.90%

Gilead Sciences Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
1,417
-4,170
1,614
1,253
1,783
1,315
1,960
3,052
2,183
Operating Cash Flow
2,169
2,219
1,325
4,309
2,975
1,757
827
4,108
3,327
Investing Cash Flow
-727
-2,207
-307
-710
-225
-415
-2,116
-427
-1,835
Financing Cash Flow
-1,099
-1,361
-2,953
-1,379
2,260
-3,426
-1,567
-1,489
-1,263
Change in Cash
380
-1,367
-1,946
2,265
4,954
-2,065
-2,782
2,186
234

Gilead Sciences Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
4,644
5,460
5,364
89
6,201
4,566
5,665
480
8,510
Operating Cash Flow
11,898
8,400
9,144
8,168
11,384
9,072
8,006
10,828
10,019
Investing Cash Flow
-16,069
14,355
-7,817
-14,615
-3,131
-2,466
-2,265
-3,449
-4,793
Financing Cash Flow
3,393
-12,318
-7,634
770
-8,877
-6,469
-5,125
-3,433
-7,745
Change in Cash
-641
10,352
-6,309
-5,634
-659
74
673
3,906
-2,427

Mutual Funds that own Gilead Sciences Inc Stock

Check out the Mutual Funds with significant holdings in Gilead Sciences Inc.

Global Institutional Holdings in Gilead Sciences Inc

Funds
Holdings
Capital World Investors
3.45%
Dimensional Fund Advisors, Inc.
0.82%
Northern Trust Corp
1.15%
UBS Asset Mgmt Americas Inc
1.05%
Capital Research Global Investors
2.42%
See all

Gilead Sciences Inc News & Key Events

  • img

    Today's Timeline - 07 April

    Tue, 05:51 PM

    -

    Gilead to acquire Tubulis for up to $5 billion, enhancing its oncology pipeline with promising cancer drugs.

    Tue, 06:20 PM

    -

    RBC adjusts Gilead's price target to $123 from $118, maintaining a sector perform rating.

    Tue, 09:36 PM

    -

    Gilead shares down 1.35% at $138.24, trading below key moving averages, indicating short-term weakness.

Insights on Gilead Sciences Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Gilead Sciences Inc. has shown consistent revenue growth over the last four quarters. The company's revenue rose from $6.66 billion to $7.92 billion, resulting in an average increase of 5.6% each quarter.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, GILD stock has moved up by 14.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, ASTRAZENECA PLC has given 198.0% return, outperforming this stock by 166.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, ASTRAZENECA PLC has given 173.8% return, outperforming this stock by 106.3%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Gilead Sciences Inc. has experienced a decline in net profit over the last two quarters. The company's net profit fell from $3.05 billion to $2.18 billion, representing an average decrease of 28.5% per quarter.

About Gilead Sciences Inc

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
OrganisationGilead Sciences Inc
Headquarters333 Lakeside Drive, Foster City, CA, United States, 94404
IndustryDrug Manufacturers - General
CEOMr. Daniel P. O'Day
E-voting on sharesClick here to vote

Key Management of Gilead Sciences Inc

Name

Title

Mr. Daniel P. O'Day

Chairman & CEO

Mr. Andrew D. Dickinson

Chief Financial Officer

Ms. Johanna Mercier

Chief Commercial & Corporate Affairs Officer

Dr. Dietmar P. Berger M.D., Ph.D.

Chief Medical Officer

Ms. Jyoti K. Mehra

Executive Vice President of Human Resources

Dr. Linda Slanec Higgins Ph.D.

Senior Vice President of Research, Innovation & Portfolio

Dr. Flavius Martin M.D.

Executive Vice President of Research

Ms. Erin E. Burkhart

Senior VP, Controller & Principal Accounting Officer

Ms. Jacquie Ross C.F.A.

Senior Vice President of Treasury & Investor Relations

Ms. Keeley M. Cain Wettan

Executive VP and General Counsel of Legal & Compliance

FAQs

What is Gilead Sciences Inc share price today?

Gilead Sciences Inc share price today is $140.43 as on at the close of the market. Gilead Sciences Inc share today touched a day high of $141.4 and a low of $137.93.

What is the 52 week high and 52 week low for Gilead Sciences Inc share?

Gilead Sciences Inc share touched a 52 week high of $157.29 on and a 52 week low of $93.37 on . Gilead Sciences Inc stock price today i.e. is closed at $140.43,which is 10.72% down from its 52 week high and 50.40% up from its 52 week low.

What is Gilead Sciences Inc's market capitalisation today?

Gilead Sciences Inc market capitalisation is $0.17T as on .

How to invest in Gilead Sciences Inc Stock (GILD) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Gilead Sciences Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Gilead Sciences Inc Shares that will get you 0.0107 shares as per Gilead Sciences Inc share price of $140.43 per share as on April 15, 2026 at 1:29 am IST.

What is the minimum amount required to buy Gilead Sciences Inc Stock (GILD) from India?

Indian investors can start investing in Gilead Sciences Inc (GILD) shares with as little as ₹93.082 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹930.82 in Gilead Sciences Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Gilead Sciences Inc share’s latest price of $140.43 as on April 15, 2026 at 1:29 am IST, you will get 0.0712 shares of Gilead Sciences Inc. Learn more about fractional shares .

What are the returns that Gilead Sciences Inc has given to Indian investors in the last 5 years?

Gilead Sciences Inc stock has given 112.91% share price returns and 24.21% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?